Artem Ivkin
Kemerovo, Please Select, 650066, Russia
Location status: Recruiting
NCT Number: NCT06525584
The study is devoted to the use of ketamine infusion in a subanesthetic dose in the postoperative period in children after surgical correction of congenital heart defects in children.
Interested in participating?
Request Info1 month–5 year
All sexes
Interventional
Not applicable
Kemerovo, Please Select, 650066, Russia
Location status: Recruiting
The study will examine the safety and effectiveness for neuroprotection of subanesthetic doses of ketamine in the postoperative period in children undergoing operations to correct septal congenital heart defects using cardiopulmonary bypass.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
ketamine infusion at a dose of 0.1 mg/kg/hour for 16 hours
Without ketamine
Time frame: 16 hours after operation
monitoring the concentration of markers of brain damage at several control points
Kemerovo State Medical University
Other
Ketamine Infusion in the Postoperative Period as a Method of Cerebral Protection in Children During Surgical Correction of Congenital Heart Defects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07577336
Acute Brain Injury, Brain Diseases
Kansas City, Missouri, United States
View Trial DetailsNCT06607523
Brain Diseases, Brain Injuries
Galveston, Texas, United States
View Trial DetailsNCT06932588
Brain Concussion, Brain Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT06413173
Attention Concentration Difficulty, Attention Impaired
San Diego, California, United States
View Trial Details